Business Context and Reporting Period
Company: Inspire Medical Systems, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2024
Event: Entry into an Accelerated Share Repurchase (ASR) agreement.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the capital allocation for the share repurchase:
- Repurchase Price: $75.0 million.
- Initial Share Delivery: Shares with an aggregate value of 80% of the Repurchase Price (based on the November 8, 2024 closing price).
- Payment Date: November 12, 2024.
Material Changes
The Company entered into an ASR agreement with Goldman Sachs & Co. LLC to repurchase $75.0 million of its common stock. This transaction is part of a previously authorized $150.0 million share repurchase program. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Transaction Terms: The final number of shares repurchased will be determined by the arithmetic average of the daily volume-weighted average prices during the transaction term, less a discount. Final settlement may result in the Company receiving additional shares or, under certain circumstances, delivering shares or cash to the counterparty.
Timeline: The transaction is scheduled to terminate in the first quarter of 2025.
Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results regarding timing and share amounts may differ materially due to risks outlined in the Company's Form 10-K and Form 10-Q filings.
Investor Verification Checklist
- Verify the closing share price on November 8, 2024, to calculate the initial number of shares received (80% of $75.0 million).
- Review the remaining balance of the $150.0 million authorized repurchase program after this $75.0 million commitment.
- Monitor future filings for the final settlement details and total share count upon termination in Q1 2025.
- Check the Company's most recent Form 10-Q for liquidity and cash position to assess the impact of the $75.0 million cash outflow.